Evidence map›Paper›PMID 23825762›Full record

ArticleJournal of thoracic disease2013

Responsiveness to leukotriene D4 and methacholine for predicting efficacy of montelukast in asthma.

Wei-Jie Guan, Jin-Ping Zheng, Yi Gao, Cai-Yu Jiang, Yan-Qing Xie, Xu Shi, Zheng Zhu, Jia-Ying An, Xin-Xin Yu, Wen-Ting Liu and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02318043 (Is Adenosine Monophosphate Superior to Histamine for Bronchial Provocation Test in Evaluation of Asthma?), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02318043 nacompletednot on this map

Is Adenosine Monophosphate Superior to Histamine for Bronchial Provocation Test in Evaluation of Asthma?

TypeinterventionalSponsorGuangzhou Institute of Respiratory DiseaseRan2007 to 2007Enrolled84ConditionsAsthmaArmsinhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg, fluticasone/salmeterol 250/50mcg)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Wei-Jie GuanState Key Laboratory of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China;
Jin-Ping Zheng
Yi Gao
Cai-Yu Jiang
Yan-Qing Xie
Xu Shi
Zheng Zhu
Jia-Ying An
Xin-Xin Yu
Wen-Ting Liu
Nan-Shan Zhong
First Affiliated Hospital of Guangzhou Medical University · CN

Funding

Therapeutic Strategy for LAM (Lymphangioleiomyomatosis)UH3TR000961 · NCATS · BAYLOR COLLEGE OF MEDICINE · PI EISSA, N. TONY · 2014 to 2016
$3.0M
Therapeutic Strategy for LAM (Lymphangioleiomyomatosis)UH2TR000961 · NCATS · BAYLOR COLLEGE OF MEDICINE · PI EISSA, N. TONY · 2013 to 2013
$1.3M
NCATS NIH HHS UH2 TR000961NCATS NIH HHS UH3 TR000961
6 · The paper itself

Abstract

A lower responsiveness to leukotriene D4 (LTD4) or higher LTD4/[methacholine (MCh)] potency ratio might suggest preferable outcomes of short-term montelukast monotherapy in terms of airway inflammation and lung function in asthmatic patients.

Indexed as

Asthmaleukotriene D4 (LTD4)leukotriene-responsiveleukotriene-unresponsivemethacholine (MCh)montelukast

Identifiers

PMID23825762
PMCPMC3698267
OpenAlexW1705962749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.